FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175172318> ?p ?o ?g. }

• W3175172318 endingPage "3196" @default.
• W3175172318 startingPage "3196" @default.
• W3175172318 abstract "Survival outcomes in ovarian cancer are poor. The aims of this Phase I progressive design study (NCT02903771) were to evaluate the maximum tolerated dose (MTD), tolerability, and antitumor activity of Cantrixil—a novel third-generation benzopyran molecule—in patients (n = 25) with advanced, recurrent/persistent epithelial ovarian, primary peritoneal, or fallopian tube cancer. All had completed ≥ 2 prior regimens; 3 (12%) had platinum-refractory disease, and 17 (68%) had platinum-resistant disease. Following intraperitoneal (IP) port placement, patients received weekly IP Cantrixil in 3-week cycles as monotherapy (Cycles 1–2), and then in combination with intravenous (IV) chemotherapy (Cycles 3–8). Part A (dose escalation) enrolled 11 patients in 6 dose-level cohorts. An MTD of 5 mg/kg was established with dose-limiting toxicity of ileus. Most treatment-related adverse events were gastrointestinal. Across Parts A and B (dose expansion), 16 (64%) patients received ≥ 1 3-week Cantrixil cycle, and had ≥ 1 post-baseline efficacy measurement available. The results show promising anti-tumor activity in monotherapy (stable disease rate of 56%) and in combination with IV chemotherapy (objective response rate of 19%, disease control rate of 56%, and median progression-free survival of 13.1 weeks). The molecular target and mechanism of action of Cantrixil are yet to be confirmed. Preliminary analysis of stem cell markers suggests that IP Cantrixil might induce ovarian cancer stem cell death and sensitize cells to standard chemotherapy, warranting further evaluation." @default.
• W3175172318 created "2021-07-05" @default.
• W3175172318 creator A5015591858 @default.
• W3175172318 creator A5017215099 @default.
• W3175172318 creator A5018355869 @default.
• W3175172318 creator A5040266917 @default.
• W3175172318 creator A5053835464 @default.
• W3175172318 creator A5062059537 @default.
• W3175172318 creator A5069337573 @default.
• W3175172318 creator A5074802129 @default.
• W3175172318 date "2021-06-26" @default.
• W3175172318 modified "2023-09-27" @default.
• W3175172318 title "Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results" @default.
• W3175172318 cites W1922469696 @default.
• W3175172318 cites W1968002492 @default.
• W3175172318 cites W1976142150 @default.
• W3175172318 cites W1983770566 @default.
• W3175172318 cites W1987904016 @default.
• W3175172318 cites W2002710053 @default.
• W3175172318 cites W2009211019 @default.
• W3175172318 cites W2020748234 @default.
• W3175172318 cites W2026862874 @default.
• W3175172318 cites W2033644156 @default.
• W3175172318 cites W2038695513 @default.
• W3175172318 cites W2076197602 @default.
• W3175172318 cites W2099373382 @default.
• W3175172318 cites W2099521317 @default.
• W3175172318 cites W2102085111 @default.
• W3175172318 cites W2104796584 @default.
• W3175172318 cites W2107400278 @default.
• W3175172318 cites W2129237375 @default.
• W3175172318 cites W2135375037 @default.
• W3175172318 cites W2142573198 @default.
• W3175172318 cites W2154175915 @default.
• W3175172318 cites W2199466904 @default.
• W3175172318 cites W2211876932 @default.
• W3175172318 cites W2279401909 @default.
• W3175172318 cites W2315075530 @default.
• W3175172318 cites W2316501478 @default.
• W3175172318 cites W2562676548 @default.
• W3175172318 cites W2599597567 @default.
• W3175172318 cites W2611236069 @default.
• W3175172318 cites W2769137962 @default.
• W3175172318 cites W2771290640 @default.
• W3175172318 cites W2801463684 @default.
• W3175172318 cites W2809499572 @default.
• W3175172318 cites W2885196309 @default.
• W3175172318 cites W2887239441 @default.
• W3175172318 cites W2889341421 @default.
• W3175172318 cites W2909429444 @default.
• W3175172318 cites W2921909640 @default.
• W3175172318 cites W2935541805 @default.
• W3175172318 cites W2952108487 @default.
• W3175172318 cites W2999297310 @default.
• W3175172318 cites W3006790259 @default.
• W3175172318 cites W3012445667 @default.
• W3175172318 cites W3027148523 @default.
• W3175172318 cites W3032982251 @default.
• W3175172318 cites W3033996966 @default.
• W3175172318 cites W3080829449 @default.
• W3175172318 cites W3117927179 @default.
• W3175172318 cites W3122624214 @default.
• W3175172318 cites W3128646645 @default.
• W3175172318 cites W3130332816 @default.
• W3175172318 cites W3137470891 @default.
• W3175172318 cites W4211139673 @default.
• W3175172318 doi "https://doi.org/10.3390/cancers13133196" @default.
• W3175172318 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8268018" @default.
• W3175172318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34206826" @default.
• W3175172318 hasPublicationYear "2021" @default.
• W3175172318 type Work @default.
• W3175172318 sameAs 3175172318 @default.
• W3175172318 citedByCount "3" @default.
• W3175172318 countsByYear W31751723182021 @default.
• W3175172318 countsByYear W31751723182022 @default.
• W3175172318 crossrefType "journal-article" @default.
• W3175172318 hasAuthorship W3175172318A5015591858 @default.
• W3175172318 hasAuthorship W3175172318A5017215099 @default.
• W3175172318 hasAuthorship W3175172318A5018355869 @default.
• W3175172318 hasAuthorship W3175172318A5040266917 @default.
• W3175172318 hasAuthorship W3175172318A5053835464 @default.
• W3175172318 hasAuthorship W3175172318A5062059537 @default.
• W3175172318 hasAuthorship W3175172318A5069337573 @default.
• W3175172318 hasAuthorship W3175172318A5074802129 @default.
• W3175172318 hasBestOaLocation W31751723181 @default.
• W3175172318 hasConcept C121608353 @default.
• W3175172318 hasConcept C126322002 @default.
• W3175172318 hasConcept C126894567 @default.
• W3175172318 hasConcept C141071460 @default.
• W3175172318 hasConcept C143998085 @default.
• W3175172318 hasConcept C197934379 @default.
• W3175172318 hasConcept C2775883341 @default.
• W3175172318 hasConcept C2776694085 @default.
• W3175172318 hasConcept C2777249960 @default.
• W3175172318 hasConcept C2778375690 @default.
• W3175172318 hasConcept C2780427987 @default.
• W3175172318 hasConcept C71924100 @default.
• W3175172318 hasConcept C90924648 @default.

• next